The global needle-free drug delivery devices market size was estimated to be USD 18.86 billion in 2023 and is expected to reach at USD 43.75 billion by 2034 with a CAGR of 7.95% during the forecast period 2024-2034. Expanding diabetic patient population, growing ease of access to Type 1 diabetes care, rising demand & technological advancements in the field of painless drug delivery & self-administration, increasing prevalence of infectious diseases such as hepatitis, dengue fever, neurological disorders, & AIDS, well-established healthcare facilities, government organizations & pharmaceutical companies are increasingly initiating efforts to fund extensive research & development costs for diabetes & chronic pain cases, surge in technological advancements in painless drug delivery, growing development of a self-administered disposable subcutaneous medication transport system, rising prevalence of chronic diseases, increasing research activities for the development of technologically advanced needle-free drug delivery devices, and surge in launch of needle-free drug delivery devices are some of the key factors boosting the market growth.
Surge in launch of needle-free drug delivery devices is predicted to boost the market growth during the forecast period. Needle-free devices offer the advantage of reducing pain and lowering the risk of infection, making them a preferred choice over conventional procedures. Consequently, there is an anticipated increase in the demand for these devices during the forecast period. For instance, in November 2023, BD (Becton, Dickinson and Company), a prominent global medical technology company, has introduced a novel needle-free blood draw technology that is designed to be used with integrated catheters. This innovation aligns with the company's objective of reducing the need for multiple needle sticks during a hospital stay. The newly developed PIVO Pro Needle-free Blood Collection Device has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). Notably, it is the first and only device compatible with both integrated and extended peripheral IV catheters, including the new Nexiva Closed IV Catheter System featuring NearPort IV Access.
By technology, transdermal patch was the highest revenue-grossing segment in the global needle-free drug delivery devices market in 2023 owing to its benefits such as the maintenance of consistent drug levels, reduced side effects, & the efficient absorption of medications that may not be effectively absorbed through the gastrointestinal tract and growing regulatory approvals. For instance, in March 2022, Corium, Inc. has been granted approval by the United States Food and Drug Administration (FDA) for ADLARITY, a donepezil transdermal system. This approval allows ADLARITY to be used as a treatment for patients with Alzheimer's disease, whether they have mild, moderate, or severe dementia. Additionally, jet injectors is predicted to grow at fastest CAGR during the forecast period owing to the rapid administration, enhanced dosing precision, quicker response times, improved tissue diffusion, decreased discomfort, reduced sharp waste, & increased portability, rising advantages of these systems over traditional needle-based drug delivery devices. These advantages encompass quicker drug delivery into the bloodstream and a wider distribution of insulin in the lower layers of an individual's skin.
By application, insulin delivery was the highest revenue-grossing segment in the global needle-free drug delivery devices market in 2023 owing to the surge in prevalence of diabetes, growing adoption of unhealthy lifestyle habits, rising introduction of technologically advanced products such as insulin spray, insulin pen, inhalable insulin, insulin micropump, & other novel jet injectors. For instance, in March 2023, NuGen Medical Devices has released a report regarding its needle-free injection device, InsuJet. According to the report, InsuJet has demonstrated more than a 40% increase in insulin uptake and a notably faster onset of action in diabetic patients when compared to traditional needle injections. These findings were observed in multiple clinical studies conducted in the Netherlands. Additionally, pain management is predicted to grow at fastest CAGR during the forecast period owing to a rising number of medical conditions, including chronic pain, pain disorders, myofascial pain syndrome, arthritis, & migraines.
By end-user, hospitals & clinics was the highest revenue-grossing segment in the global needle-free drug delivery devices market in 2023 owing to the growing prevalence of chronic diseases, increasing adoption of technologically advanced devices, and rising regulatory approvals. Additionally, homecare settings is predicted to grow at fastest CAGR during the forecast period owing to the benefits of needle-free drug delivery devices include precise dosage administration, reduced pain for patients leading to improved outcomes, faster drug delivery for quicker effects, and cost-effectiveness and surge in collaborations within market players. For instance, in May 2022, Zealand Pharma A/S has entered into an asset purchase agreement with MannKind Corporation to sell the V-Go insulin delivery device for $10 million, with the potential for additional sales-based milestones. The V-Go is a wearable, patch-like insulin delivery device designed for once-daily use to aid in insulin administration.
North America region is anticipated for the highest revenue share during the forecast period owing to the presence of well-established healthcare facilities, government organizations & pharmaceutical companies are investing heavily in research & development for the management of diabetes & chronic pain, growing burden of chronic diseases such as diabetes, surge in approvals for needle-free drug delivery devices, and rising initiatives by market players. For instance, in June 2022, NovaXS Biotech has unveiled the prototype for its innovative needle-free injection therapy smart medical device. This device, named Telosis, incorporates patent-pending technology that delivers a narrow stream of medication in just 0.3 seconds, all without the need for a needle. Additionally, it assesses injection data to support informed medical decisions. The company asserts that its technology provides a straightforward and painless alternative for at-home medication delivery, making it the first remote medication and self-administration monitoring platform. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the surge in prevalence of diabetes, increasing awareness regarding potential benefits of needle-free drug delivery devices, growing research & development activities for the innovative of advanced devices, and rising launch of new products. For instance, in November 2023, NiedlFree Technologies, a company based in Hyderabad and affiliated with Transgene Biotek, has achieved significant advancements in the field of diabetes treatment. They assert that they have created Ozulin, a painless and needle-free oral insulin spray. This innovative product is designed for use by both animals and humans, offering a promising development in diabetes management.
Surge in launch of needle-free drug delivery devices is predicted to boost the market growth during the forecast period. Needle-free devices offer the advantage of reducing pain and lowering the risk of infection, making them a preferred choice over conventional procedures. Consequently, there is an anticipated increase in the demand for these devices during the forecast period. For instance, in November 2023, BD (Becton, Dickinson and Company), a prominent global medical technology company, has introduced a novel needle-free blood draw technology that is designed to be used with integrated catheters. This innovation aligns with the company's objective of reducing the need for multiple needle sticks during a hospital stay. The newly developed PIVO Pro Needle-free Blood Collection Device has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). Notably, it is the first and only device compatible with both integrated and extended peripheral IV catheters, including the new Nexiva Closed IV Catheter System featuring NearPort IV Access.
By technology, transdermal patch was the highest revenue-grossing segment in the global needle-free drug delivery devices market in 2023 owing to its benefits such as the maintenance of consistent drug levels, reduced side effects, & the efficient absorption of medications that may not be effectively absorbed through the gastrointestinal tract and growing regulatory approvals. For instance, in March 2022, Corium, Inc. has been granted approval by the United States Food and Drug Administration (FDA) for ADLARITY, a donepezil transdermal system. This approval allows ADLARITY to be used as a treatment for patients with Alzheimer's disease, whether they have mild, moderate, or severe dementia. Additionally, jet injectors is predicted to grow at fastest CAGR during the forecast period owing to the rapid administration, enhanced dosing precision, quicker response times, improved tissue diffusion, decreased discomfort, reduced sharp waste, & increased portability, rising advantages of these systems over traditional needle-based drug delivery devices. These advantages encompass quicker drug delivery into the bloodstream and a wider distribution of insulin in the lower layers of an individual's skin.
By application, insulin delivery was the highest revenue-grossing segment in the global needle-free drug delivery devices market in 2023 owing to the surge in prevalence of diabetes, growing adoption of unhealthy lifestyle habits, rising introduction of technologically advanced products such as insulin spray, insulin pen, inhalable insulin, insulin micropump, & other novel jet injectors. For instance, in March 2023, NuGen Medical Devices has released a report regarding its needle-free injection device, InsuJet. According to the report, InsuJet has demonstrated more than a 40% increase in insulin uptake and a notably faster onset of action in diabetic patients when compared to traditional needle injections. These findings were observed in multiple clinical studies conducted in the Netherlands. Additionally, pain management is predicted to grow at fastest CAGR during the forecast period owing to a rising number of medical conditions, including chronic pain, pain disorders, myofascial pain syndrome, arthritis, & migraines.
By end-user, hospitals & clinics was the highest revenue-grossing segment in the global needle-free drug delivery devices market in 2023 owing to the growing prevalence of chronic diseases, increasing adoption of technologically advanced devices, and rising regulatory approvals. Additionally, homecare settings is predicted to grow at fastest CAGR during the forecast period owing to the benefits of needle-free drug delivery devices include precise dosage administration, reduced pain for patients leading to improved outcomes, faster drug delivery for quicker effects, and cost-effectiveness and surge in collaborations within market players. For instance, in May 2022, Zealand Pharma A/S has entered into an asset purchase agreement with MannKind Corporation to sell the V-Go insulin delivery device for $10 million, with the potential for additional sales-based milestones. The V-Go is a wearable, patch-like insulin delivery device designed for once-daily use to aid in insulin administration.
North America region is anticipated for the highest revenue share during the forecast period owing to the presence of well-established healthcare facilities, government organizations & pharmaceutical companies are investing heavily in research & development for the management of diabetes & chronic pain, growing burden of chronic diseases such as diabetes, surge in approvals for needle-free drug delivery devices, and rising initiatives by market players. For instance, in June 2022, NovaXS Biotech has unveiled the prototype for its innovative needle-free injection therapy smart medical device. This device, named Telosis, incorporates patent-pending technology that delivers a narrow stream of medication in just 0.3 seconds, all without the need for a needle. Additionally, it assesses injection data to support informed medical decisions. The company asserts that its technology provides a straightforward and painless alternative for at-home medication delivery, making it the first remote medication and self-administration monitoring platform. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the surge in prevalence of diabetes, increasing awareness regarding potential benefits of needle-free drug delivery devices, growing research & development activities for the innovative of advanced devices, and rising launch of new products. For instance, in November 2023, NiedlFree Technologies, a company based in Hyderabad and affiliated with Transgene Biotek, has achieved significant advancements in the field of diabetes treatment. They assert that they have created Ozulin, a painless and needle-free oral insulin spray. This innovative product is designed for use by both animals and humans, offering a promising development in diabetes management.
Segmentation: Needle-Free Drug Delivery Devices Market Report 2023 - 2034
Needle-Free Drug Delivery Devices Market Analysis & Forecast by Technology 2023 - 2034 (Revenue USD Bn)
- Transdermal Patch
- Inhaler
- Jet Injectors
- Novel Needle
- Others
Needle-Free Drug Delivery Devices Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Pain Management
- Insulin Delivery
- Vaccine Delivery
- Pediatric Injections
- Others
Needle-Free Drug Delivery Devices Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Homecare Settings
- Academics
- Hospitals & Clinics
- Research Laboratories
- Others
Needle-Free Drug Delivery Devices Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Needle-Free Drug Delivery Devices Market: Technology Estimates & Trend Analysis
8. Needle-Free Drug Delivery Devices Market: Application Estimates & Trend Analysis
9. Needle-Free Drug Delivery Devices Market: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Needle-Free Drug Delivery Devices Market
12. Europe Global Needle-Free Drug Delivery Devices Market
13. Asia Pacific Global Needle-Free Drug Delivery Devices Market
14. Latin America Global Needle-Free Drug Delivery Devices Market
15. MEA Global Needle-Free Drug Delivery Devices Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- PharmaJet
- Halozyme Inc. (Antares Pharma)
- Crossject
- 3M
- PenJet Corporation
- MannKind Corporation
- Zealand Pharma A/S
- Zydus Group
- Mika Medical Co.
- Ferring B.V.
- Akra Dermojet
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 18.86 Billion |
| Forecasted Market Value ( USD | $ 43.75 Billion |
| Compound Annual Growth Rate | 7.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
